Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;13 Suppl 1(Suppl 1):663-73.

The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy

Debra S Regier, Richard L Proia, Alessandra D'Azzo, Cynthia J Tifft
Review

The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy

Debra S Regier et al. Pediatr Endocrinol Rev. 2016 Jun.

Abstract

The gangliosidoses are lysosomal storage disorders caused by accumulation of GM1 or GM2 gangliosides. GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system. Both disorders have autosomal recessive modes of inheritance and a continuum of clinical presentations from a severe infantile form to a milder, chronic adult form. Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases. Naturally occurring and engineered animal models that mimic the human diseases have enhanced our understanding of the pathogenesis of disease progression. Some models have shown significant improvement in symptoms and lifespan with enzyme replacement, substrate reduction, and anti-inflammatory treatments alone or in combination. More recently gene therapy has shown impressive results in large and small animal models. Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients. Therapies also under clinical development include small molecule chaperones and gene therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors have no conflicts of interest to declare

Figures

Figure 1.
Figure 1.. Sphingolipid Catabolism
GM1 ganglioside is metabolized by β-galactosidase to form GW2 ganglioside. Abnormalities of this metabolic step lead to accumulation of GM1 ganglioside and GM1 gangliosidosis. GM2 ganglioside is converted to GM3 ganglioside by the action of β-hexosaminidase A. Deficiencies of this enzyme result in the accumulation of GM2 ganglioside and Tay-Sachs or Sandhoff disease
Figure 2.
Figure 2.. GM1 Gangliosidosis
NEU1, PCCA, and β-GAL assemble in the lysosome. This complex is required for β-GAL to convert GM1 to GM2 ganglioside. Alternate splicing of BGAL leads to formation of EBP. This forms a membrane-associated complex with PCCA and NEU1 to metabolize tropoelastin to elastin fibers
Figure 3.
Figure 3.. GM2 Gangliasidoses
Deficiencies in β-hexosaminidase A resulting from mutations in either HEX A (β subunit) or HEX B (β subunit) lead to Tay Sachs or Sandhoff disease respectively. Mutations in GM2A (GM2 activator protein) lead to GM2 activator deficiency.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Regier DS, Tifft CJ. GLB1-Related Disorders. In: GeneReviews(R). Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Smith RJH, Stephens K. Seattle (WA) 2013
    1. Regier DS, Oetgen M, Tanpaiboon P. Mucopolysaccharidosis Type IVA. In: GeneReviews(R). Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K. Seattle (WA) 2015
    1. Schulze H, Sandhoff K. Sphingolipids and lysosomal pathologies. Biochim Biophys Acta 2014;1841:799–810 - PubMed
    1. Hofer D, Paul K, Fantur K, Beck M, Roubergue A, Vellodi A, Poorthuis BJ, Michelakakis H, Plecko B, Paschke E. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. Clinical Genetics 2010;78:236–246 - PubMed
    1. Caciotti A, Garman SC, Rivera-Colon Y, Procopio E, Catarzi S, Ferri L, Guido C, Martelli P, Parini R, Antuzzi D, Battini R, Sibilio M, Simonati A, Fontana E, Salviati A, Akinci G, Cereda C, Dionisi-Vici C, Deodato F, d’Amico A, d’Azzo A, Bertini E, Filocamo M, Scarpa M, di Rocco M, Tifft CJ, Ciani F, Gasperini S, Pasquini E, Guerrini R, Donati AAA, Morrone A. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochimica et Biophysica Acta 2011;1812:782–790 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources